Increases in drug prices are of concern to worldwide health systems

By HEOR Staff Writer

March 17, 2023

In surveys of ISPOR members, drug pricing was revealed to be a major concern, and one of the top 10 health economics and outcomes research issues influencing the availability of innovative treatments and healthcare decisions.

Despite the fascinating ways that different research studies proposed to understand the puzzle of drug pricing, it is evident that drug prices must factor in the research uncertainties and other costs in addition to the cost of clinical trials and production and should be set to yield an acceptable return on investment.

There has been a lot of discussion about the fairness of drug pricing. The concept is multifaceted, and when discussing it, drug characteristics and market forces must be included. This conversation is further complicated by the lack of transparency in drug pricing and the rise in drug prices.

It is likely that the debate will persist.

Reference url

Recent Posts

EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles

By João L. Carapinha

March 26, 2026

Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector

By João L. Carapinha

South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...